Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles

Journal of Nuclear Medicine

Volumn 57, Issue 10, 2016, Pages 1599-1606

  Hostetler, Eric D ^a   Walji, Abbas M ^a   Zeng, Zhizhen ^a   Miller, Patricia ^a   Bennacef, Idriss ^a   Salinas, Cristian ^a   Connolly, Brett ^a   Gantert, Liza ^a   Haley, Hyking ^a   Holahan, Marie ^a   Purcell, Mona ^a   Riffel, Kerry ^a   Lohith, Talakad G ^a   Coleman, Paul ^a   Soriano, Aileen ^a   Ogawa, Aimie ^a   Xu, Serena ^a   Zhang, Xiaoping ^a   Joshi, Elizabeth ^a   Della Rocca, Joseph ^a   Hesk, David ^a   Schenk, David J ^a   Evelhoch, Jeffrey L ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

18F; Alzheimer's disease; Neurofibrillary tangles; PET; Tau

Indexed keywords

6 (FLUORO) 3 (1H PYRROLO[2,3 C]PYRIDIN 1 YL)ISOQUINOLIN 5 AMINE; 6 (FLUORO) 3 (1H PYRROLO[2,3 C]PYRIDIN 1 YL)ISOQUINOLIN 5 AMINE F 18; 6 (FLUORO) 3 (1H PYRROLO[2,3 C]PYRIDIN 1 YL)ISOQUINOLIN 5 AMINE H 3; AMYLOID PROTEIN; FLUORINE 18; TAU PROTEIN; TRACER; TRITIUM; UNCLASSIFIED DRUG; ISOQUINOLINE DERIVATIVE; MK-6240;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BRAIN CORTEX; BRAIN SLICE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SELECTIVITY; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NEUROFIBRILLARY TANGLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RHESUS MONKEY; TISSUE HOMOGENATE; ANIMAL; AUTORADIOGRAPHY; BRAIN; CHEMISTRY; DIAGNOSTIC IMAGING; MALE; METABOLISM; PATHOLOGY; PROCEDURES; RADIOCHEMISTRY;

ANIMALS; AUTORADIOGRAPHY; BRAIN; HUMANS; ISOQUINOLINES; MACACA MULATTA; MALE; NEUROFIBRILLARY TANGLES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOCHEMISTRY;

EID: 84991404463     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.171678     Document Type: Article

References (29)

1. Villain N, Chetelat G, Grassiot B, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126-2139.
2. Toledo JB, Xie SRX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF tau and a-beta biomarkers for up to 48 months in ADNI. Acta Neuropathol (Berl). 2013;126:659-670.
3. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362-381.
4. Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimers-disease. Arch Neurol. 1995;52:81-88.
5. Ariza M, Kolb HC, Moechars D, Rombouts F, Andres JI. Tau positron emission tomography (PET) imaging: past, present, and future. J Med Chem. 2015;58:4365-4382.
6. Shah M, Catafau AM. Molecular imaging insights into neurodegeneration: focus on tau PET radiotracers. J Nucl Med. 2014;55:871-874.
7. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457-468.
8. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787-800.
9. Vermeiren C, Mercier J, Viot D, et al. T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase A. Alzheimers Dement. 2015;11:P283.
10. Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171-184.
11. Harada R, Okamura N, Furumoto S, et al. F-18-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208-214.
12. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094-1108.
13. Walji AM, Hostetler ED, Greshock T, et al., inventors; Merck Sharp and Dohme Corp, assignee. Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrilary tangles. International patent WO2015/191506A2. December 17, 2015.
14. Walji AM, Hostetler ED, Greshock T, et al., inventors; Merck Sharp and Dohme Corp, assignee. Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrilary tangles. International patent WO2015/188368A1. December 17, 2015.
15. Hostetler ED, Hamill TG, Francis BE, Burns HD. A versatile, commercially available automated synthesizer for the development and production of PET radiotracers. J Labelled Comp Radiopharm. 2001;44:S1042-S1044.
16. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
17. Hostetler ED, Sanabria-Bohorquez S, Fan H, et al. [F-18]fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey. Nucl Med Biol. 2011;38:1193-1203.
18. Hamill TG, Sato N, Jitsuoka M, et al. Histamine H3 inverse agonist PET tracers labelled with carbon-11 or fluorine-18. Neuroimage. 2008;41:T22-T22.
19. Yamazaki M, Neway WE, Ohe T, et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001;296:723-735.
20. National Research Council. Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, D.C.: National Academies Press; 2011.
21. Hostetler ED, Sanabria-Bohorquez S, Fan H, et al. [F-18]fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey. Nucl Med Biol. 2011;38:1193-1203.
22. Patel S, Gibson R. In vivo site-directed radiotracers: a mini-review. Nucl Med Biol. 2008;35:805-815.
23. Jicha GA, Abner EL, Schmitt FA, et al. Preclinical AD workgroup staging: pathological correlates and potential challenges. Neurobiol Aging. 2012;3:622.e1.
24. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A Quantitative model for the in vivo assessment of drug-binding sites with positron emission tomography. Ann Neurol. 1984;15:217-227.
25. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
26. Lemoine J, Saint-Aubert L, Marutle A, et al. Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue. Acta Neuropathal Commun. 2015;3:40.
27. Xia CF, Arteaga J, Chen G, et al. [F-18]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666-676.
28. Bergström M, Westerberg G, Langstrom B. C-11-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies. Nucl Med Biol. 1997;24:287-293.
29. Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA. 1996;93:14065-14069.